Related Experiment Videos
Radioimmunoscintigraphy with a novel monoclonal antiprostate antibody (E4): an experimental study in nude mice
A Rydh1, K Riklund Ahlström, A Widmark
1Department of Diagnostic Radiology, University Hospital of Northern Sweden, Umeå.
Background:
Prostate cancer is one of the leading causes of death among men, despite achievements in diagnosis and therapy. Radioimmunolocalization and radioimmunotherapy of malignant tumors have demonstrated increasing potential and may become useful tools in the management of prostate cancer.
Methods:
Nude mice were inoculated subcutaneously with cells from the poorly differentiated human prostate cancer cell line DU-145. The intact monoclonal antibody (MoAb) E4 and an intact anticytokeratin-8 MoAb, TS1, used for comparison were labeled with 125I and injected intraperitoneally (i.p.) in the mice. Repetitive quantitative scintigraphic recordings were performed during 1 month. The mice were killed at Day 29 after injection of the radiolabeled MoAb. The tumors and the organs were dissected and weighed. The remaining activity was measured in a gamma well counter. One part of the tumor was immediately fixed in Bouin's solution for autoradiography and the other in formaldehyde for microscopy.
Results:
The study demonstrated significant radioimmunolocalization of the MoAb E4 into the DU-145 prostate tumor tissue in the animal model, with an average radiation dose of 0.08 Gy/MBq in the tumor. TS1 localized preferentially in necrotic parts of the tumor, yielding a tumor dose of 0.02 Gy/MBq.
Conclusions:
The MoAb E4 is a promising radiotracer for prostate cancer and may be used in radioimmunotherapy. As in earlier studies, TS1 shows significant radioimmunolocalization into necrotic tumor tissue, which also exists in prostate cancer.
Insights
Monoclonal antibody (MoAb) E4 shows promise for prostate cancer diagnosis and therapy. This study demonstrated its effective radioimmunolocalization in a DU-145 tumor model, suggesting potential for radioimmunotherapy.
Area of Science:
- Oncology
- Immunology
- Nuclear Medicine
Background:
- Prostate cancer remains a significant cause of mortality in men.
- Radioimmunolocalization and radioimmunotherapy offer potential advancements in managing prostate cancer.
Purpose of the Study:
- To evaluate the efficacy of monoclonal antibody (MoAb) E4 for radioimmunolocalization of prostate cancer.
- To compare MoAb E4 with an anticytokeratin-8 MoAb (TS1) in a preclinical model.
Main Methods:
- DU-145 human prostate cancer cells were xenografted into nude mice.
- Intact MoAb E4 and TS1 were labeled with 125I and administered intraperitoneally.
- Quantitative scintigraphy, biodistribution studies, and histological analysis were performed.
Main Results:
- MoAb E4 demonstrated significant radioimmunolocalization in DU-145 prostate tumors (0.08 Gy/MBq).
- TS1 showed preferential localization in necrotic tumor regions (0.02 Gy/MBq).
Conclusions:
- MoAb E4 is a promising radiotracer for prostate cancer detection and potential radioimmunotherapy.
- TS1 also localized to necrotic tumor tissue, consistent with previous findings.